AR085041A1 - Inhibidores de caspasa-2 - Google Patents
Inhibidores de caspasa-2Info
- Publication number
- AR085041A1 AR085041A1 ARP120100298A ARP120100298A AR085041A1 AR 085041 A1 AR085041 A1 AR 085041A1 AR P120100298 A ARP120100298 A AR P120100298A AR P120100298 A ARP120100298 A AR P120100298A AR 085041 A1 AR085041 A1 AR 085041A1
- Authority
- AR
- Argentina
- Prior art keywords
- caspase
- independently selected
- different
- same
- caspasa
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004046 Caspase-2 Human genes 0.000 abstract 3
- 108090000552 Caspase-2 Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000861 pro-apoptotic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22055—Caspase-2 (3.4.22.55)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos, composiciones farmacéuticas y uso de los mismos, que inhiben caspasa-2 proapoptótica para prevenir y/o tratar enfermedades y lesiones en donde está implicada la actividad de caspasa-2, en particular isquemia cerebral neonatal.Reivindicación 1: Un compuesto que tiene una actividad inhibitoria de caspasa-2 caracterizado porque es de fórmula general (1) en donde: n es 0 ó 1; A representa N, N(H), O, S, o N-O (es decir N-óxido); - - - - - adyacente al grupo A puede ser un enlace simple cuando A es O ó S o un enlace simple o doble cuando A es N(H) o N, respectivamente; X, el mismo o diferente uno del otro, se selecciona independientemente de átomos de halógeno; X1 representa H o un átomo de halógeno, y R1, el mismo o diferente uno del otro, se selecciona independientemente de H y un grupo alquilo C1-4 lineal o ramificado; y sales y/o solvatos del mismo farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11152892 | 2011-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085041A1 true AR085041A1 (es) | 2013-08-07 |
Family
ID=45688443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100298A AR085041A1 (es) | 2011-02-01 | 2012-01-30 | Inhibidores de caspasa-2 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120196892A1 (es) |
| EP (1) | EP2670774A1 (es) |
| KR (1) | KR20140005215A (es) |
| CN (1) | CN103339144A (es) |
| AR (1) | AR085041A1 (es) |
| BR (1) | BR112013019061A2 (es) |
| CA (1) | CA2826200A1 (es) |
| RU (1) | RU2013136045A (es) |
| WO (1) | WO2012104224A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
| WO2017162674A1 (en) | 2016-03-22 | 2017-09-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Novel derivatives and their use as selective inhibitors of caspase-2 |
| KR102823028B1 (ko) * | 2017-09-26 | 2025-06-19 | 상뜨르 나쇼날 드 라 러쉐르쉬 샹띠피끄(씨엔알에스) | 카스파제-2 의 선택적 억제제로서의 신규 화합물 및 그 용도 |
| EP4112631A1 (en) | 2021-07-01 | 2023-01-04 | Kintsugi Therapeutics S.L. | Caspase-2 inhibitor compounds |
| EP4397674A1 (en) | 2023-01-03 | 2024-07-10 | Kintsugi Therapeutics S.L. | Caspase-2 inhibitor compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4991297B2 (ja) | 2003-05-22 | 2012-08-01 | キエジ ファルマチェウティチ エッセ・ピ・ア | 細胞死を予防および治療するための手段およびそれらの生物学的適用 |
| EP1740614A2 (en) | 2004-04-30 | 2007-01-10 | Theraptosis S.A. | Caspase-2 inhibitors and their biological applications |
| WO2006056487A2 (en) | 2004-11-24 | 2006-06-01 | Theraptosis S.A. | Peptides useful as dual caspase-2/-6 inhibitors and their biological applications |
| EP2173384A2 (en) * | 2007-06-27 | 2010-04-14 | CHIESI FARMACEUTICI S.p.A. | Caspase inhibitors for treating pathologies resulting from ischemia |
-
2012
- 2012-01-27 BR BR112013019061A patent/BR112013019061A2/pt not_active IP Right Cessation
- 2012-01-27 WO PCT/EP2012/051367 patent/WO2012104224A1/en not_active Ceased
- 2012-01-27 RU RU2013136045/04A patent/RU2013136045A/ru not_active Application Discontinuation
- 2012-01-27 EP EP12704726.4A patent/EP2670774A1/en not_active Withdrawn
- 2012-01-27 KR KR1020137019588A patent/KR20140005215A/ko not_active Withdrawn
- 2012-01-27 CN CN2012800070770A patent/CN103339144A/zh active Pending
- 2012-01-27 CA CA2826200A patent/CA2826200A1/en not_active Abandoned
- 2012-01-30 AR ARP120100298A patent/AR085041A1/es not_active Application Discontinuation
- 2012-01-31 US US13/362,104 patent/US20120196892A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013019061A2 (pt) | 2018-06-26 |
| WO2012104224A1 (en) | 2012-08-09 |
| US20120196892A1 (en) | 2012-08-02 |
| RU2013136045A (ru) | 2015-02-10 |
| CA2826200A1 (en) | 2012-08-09 |
| CN103339144A (zh) | 2013-10-02 |
| EP2670774A1 (en) | 2013-12-11 |
| KR20140005215A (ko) | 2014-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13012363A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| NI201200191A (es) | Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica | |
| ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
| JOP20190115B1 (ar) | مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp) | |
| MX2017004906A (es) | Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma. | |
| CR20170367A (es) | Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1 | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| CO7160104A2 (es) | Inhibidores de virus de hepatitis c | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2017016344A (es) | Compuestos de benzoxacepina oxazolidinona y metodos de uso. | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| UY37028A (es) | Compuestos inhibidores de prostaglandina d sintasa ematopoyética (h-pgds | |
| MX2016016516A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| UY32793A (es) | Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos | |
| MX383686B (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| MD4556C1 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
| MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| MX2016016528A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| GT201700099A (es) | 2- amino-6-(difluorometil)-5,5-difluoro-6-fenil-3, 4, 5, 6-tetrahidropiridinas como inhibidores de bace1 | |
| MA43120A (fr) | Dérivé tricyclique contenant de l'azote présentant une activité inhibitrice de la réplication du vih | |
| UY33655A (es) | Co-cristales y sales de inhibidores de ccr30 | |
| CU24330B1 (es) | Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral) | |
| GEAP201914608A (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |